Archive · 25 Jun 2025
Sun Pharma Partner Withdraws Skin Cancer Therapy Application in Europe
Imagine a company making medicine for skin cancer, specifically a type called melanoma.
They asked Europe if they could sell this medicine, but they needed to give more information.
The company decided to pause their application because they needed to collect more information and the timing wasn't right.
They plan to apply again later.
This medicine has already been used for other skin cancers in over 450 patients.
This pause is a temporary step to ensure everything is perfect before the medicine is available to patients.
Sun Pharma's European partner, Philogen, withdrew its marketing authorization application for Nidlegy.
Nidlegy is an investigational therapy for the treatment of locally advanced melanoma.
The withdrawal was due to timing of data and clinical information.
The therapy is co-developed by Sun Pharma and Philogen.
Philogen plans to resubmit an updated application.
- Who
- Sun Pharmaceutical Industries Ltd. and its partner Philogen
- What
- Philogen withdrew the marketing authorization application for Nidlegy.
- When
- The application was withdrawn in June 2024.
- Where
- Europe
- Why
- Due to the timing of availability of data and clinical information.
- Company
- Sun Pharmaceutical Industries Ltd., Philogen
- Therapy
- Nidlegy
- Target
- Locally advanced, resectable melanoma
- Application Status
- Withdrawn, resubmission planned
- Patients Treated
- More than 450